Analysts expect Clover Health to report Q3 2026 consensus revenue of $740.31 million and an EPS of -$0.01, with the current stock price of $4.79 trading below the $5.25 median analyst target.
Investors are primarily focused on the Medical Benefit Ratio (MBR) to determine if the company's technology-driven cost-containment measures can sustain the margin improvements achieved earlier this year.
Following a strong first half, management recently raised full-year 2026 consolidated gross profit guidance to a range of $525 million to $555 million. This report will serve as a critical test of whether Clover's "Clover Assistant" platform can successfully offset the typical seasonal increase in medical costs expected during the latter half of the fiscal year.